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Abbreviations: 
CT: Computed  Tomography 
MR: Magnetic Resonance 
I: Imaging 
RECIST: Response Evaluation Criteria in Solid Tumors 
DWI: Diffusion-Weighted Imaging 
HU: Hounsfield Unit 
CA: Contrast Agent 
ADC: Apparent Diffusion Coefficient  
PF: Perfusion Fraction  
D: Diffusion Coefficient 
D*: Fast Diffusion Coefficient 
 Gd-EOB-DTPA: Gadoxetic Acid  
ROI: Region of Interest  
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1.Preface 
1.1. New technologies applications  
Progress in therapies, should be matched with progress in radiology imaging. For instance, 
morphological information in the follow up CT/MRI for cancer now seems to be 
inadequate.  
The Response Evaluation Criteria in Solid Tumors (RECIST), is described in several 
articles and recommended for estimating tumor response to therapies based on the lesion 
size [1]. The RECIST assessment with morphologic imaging techniques, such as CT or 
MRI, has limitations mainly due to the morphological evaluation and in differentiating 
necrotic tumor or fibrotic scar from residual tumor tissue. Furthermore, some of the new 
targeted therapies are cytostatic rather than cytoreductive. In these applications successful 
treatment does not reduce the tumor size, and, therefore, new issues on imaging techniques 
rise [2].   
New Imaging applications such as Diffusion, Spectroscopy and Perfusion attempt to 
provide quantitative and functional data. 
Perfusion, in particular, is known since the ’80, after the introduction of CT technology,  
when Leon Axel, first proposed a method for determining tissue perfusion from dynamic 
contrast enhanced CT data [3]. For many years, this application has not evolved but, 
nowadays, the possibility of rapid Imaging with multi-slice CT and the availability of  
more sophisticated analysis software made the Perfusion Imaging with CT possible. Its 
applications in the neurological field and body Imaging is part of daily practice.   
As well, Diffusion MRI (DWI) is a method which came into existence in the mid-1980s [4-
5]. This application allows the mapping of the diffusion process of molecules, mainly 
water, in biological tissues, in vivo and non-invasively. 
Diffusion, Spectroscopy and Perfusion have been proposed, in oncology, in order to find 
an Imaging correlate for tumor characterization (to discriminate benign and malignant 
lesions) and , at the same time, an indicator of tumor aggressiveness. Moreover, the 
information provided can be useful for a functional assessment of tumor response to 
therapy.  The ability to identify changes in a tumor’s perfusion offers the potential to 
predict growth or regression. With this data, clinicians could offer more tailored treatment, 
which might ultimately improve patient’s outcomes.  
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In light for this, recently the Imaging is focusing on new fields. Modern software, which 
still have to be validated, are now available, promising to provide quantitative and 
functional information. 
During my PhD, I mainly studied the Perfusion and the Diffusion, while I could not study 
the Spectroscopy, failing an adequate equipment, which remains one of the most promising 
MRI applications. 
 
• Perfusion is based on the assessment of the contrastographic dynamic curves and 
can identify areas of increased or reduced blood perfusion (for example neoplasms may 
show an early and strong contrast enhancement mainly due to the neoangiogenesis 
processes). Highly vascularized tumors are often associated with a poor prognosis and high 
capability of metastasis. Perfusion is able to detect early changes in the microcirculation. 
Several studies demonstrated that in pathological conditions, such as cirrhosis, perfusion 
parameters change significantly (decrease in portal and hepatic flow, increase in arterial 
perfusion and the mean transit time) depending on the severity of the  disease (related to 
Child-Pugh) [6]. There is a relationship between the presence of tissue modifications and 
Perfusion changes. There are many available CT software dedicated to Perfusion Imaging 
based on the hypothesis that the concentration of the contrast agent (CA) and variation of 
density attenuation values, measured in Hounsfield Units (HU),  are directly proportional. 
Recording the first pass of the CA bolus through the vascular system we can estimate the 
time-attenuation curves. The data obtained are theoretically comparable and reproducible.  
Then, the parameters such as BF (Blood Flow: blood flow velocity), BV (Blood Volume: 
blood volume), PS (Permeability Surface: interstitial permeability), and MTT (mean transit 
time: mean transit time of the contrast in the analyzed volume) can be obtained. High BF 
correlates with the presence of a low resistance to the flow due to arteriovenous shunts, 
which determines an increase in the flow velocity and consequently a low MTT. A high 
BV may indicate a vascular angiogenesis and a high PS indicates an increase in capillary 
permeability typical of tumor tissues. This method, therefore, appears to be useful for the 
characterization of lesions, therapeutic planning and monitoring of cancer therapies [6].  
• Diffusion-weighted Imaging can study water diffusion properties of examined 
tissue. This approach is based on the measurement of Brownian motion of molecules. It 
has been known for a long time  even though superficially, that nuclear magnetic 
resonance is capable of quantifying diffusional movement of molecules. It is possible to 
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use this diffusion property as a probe to study the structure of spatial order in living organs 
noninvasively [7]. 
• Magnetic resonance spectroscopy (MRS) is a non-invasive technique that allows to 
obtain biochemical information from tissues and organs. This method provides the relief 
and measurement of known metabolites present in the studied tissue volume. The signal, 
arising from different isotopes (H, P, C13 etc.), is recognizable because isotopes resonate 
at known frequencies when placed in a magnetic field. The equipment necessary for this 
type of study is a high field (1.5 / 3 T) and the related  software [8].   
 
1.2. Role of CT and MRI 
I'm a slow walker, but I never walk back. 
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Perfusion can be studied in both CT and MRI. The first field of Perfusion application was 
the Neurology Imaging but promising employments are for Cardiology and Oncology 
Imaging.  
The basis for the use of Perfusion in Oncology is that the microvascular changes in 
angiogenesis are reflected by increased tumor perfusion in vivo.  
The CT Perfusion is based on “the principle of central volume” (which put in correlation 
blood flow, blood volume and mean transit time in the equation: BF= BV/MTT) . The 
assumptions are that the contrast agent:1) completely mixes with the blood, 2) during the 
first pass is completely intravascular, 3) CT attenuation values reflects accurately the 
concentration of the contrast medium, and 4) through the vascular bed this does not cause 
hemodynamic or physiologic changes.  
Because of its linearity, CT is of advantage on MRI, where this relationship does not exist 
[9].  Therefore, CT employment has gained wider acceptances, than MRI. At the beginning 
of my PhD, our group studied this technique on oncologic patients with the aim at finding 
a possible application  of CT Perfusion during the early monitoring of chemotherapy. 
Unfortunately, the first data showed the following issues:  
- lack of  reproducibility,  
- high radiation doses,  
                                                 
1
 Abraham Lincoln 
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- need of high CA flow.  
As a consequence, we decided to interrupt the study and focus our efforts in validating the 
Diffusion. 
In fact, Diffusion, is of particular interest because it  allows to examine, at molecular level, 
what happen in the tissues,  providing data that might be important in the early diagnosis of 
diseases. 
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2. Personal Experience  
2.2. Abstract 
Purpose:  
The purpose of this study was to verify the influence of age and Gadoxetic Acid (Gd-EOB-
DTPA; Primovist, Bayer-Schering, Berlin, Germany) on DWI-related parameters: apparent 
diffusion coefficient (ADC), perfusion fraction (PF), diffusion and fast diffusion 
coefficient (D and D*) using the Le Bihan IntraVoxel Incoherent Motion method. 
Materials and Methods:  
To investigate the influence of age on the diffusion parameters, forty healthy adult 
volunteers, divided into four age groups, were prospectively submitted to a breath-hold 
MR-DWI (two b values 0–300 and 0–1000 s/mm2 and a free-breath multi-b acquisition 16 
b values, 0–750 s/mm2) -to investigate the influence of Gadoxetic Acid on the diffusion 
parameters, twenty-four consecutive patients, were prospectively submitted to MR-DWI 
acquisition before and after gadoxetic acid administration. The patients were divided into 
four groups according to the time at which the DW sequence was repeated (5, 10, 15, 20 
minutes after contrast agent administration).  
Quantitative analysis was performed by two observers with manually defined regions of 
interest (ROIs), in the most homogeneous portion of the right liver lobe. The mean and 
standard deviation (SD) were calculated in each group/patient for every DWI related 
parameter.  
Results:  
ANOVA showed no significant differences among age groups (p n.s.). Moreover, D, D*, 
PF, and ADC did not show any significant difference before and after contrast agent 
administration, at any time. 
Conclusions:  
No significant correlation between subjects’ age and DW 
I parameters were observed, both in breath-hold and freebreath acquisitions.  
It is possible to perform DW acquisitions after gadoxetic acid administration without any 
significant variation in the values of DW-related parameters. 
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2.3. Keywords 
DWI; quantitative DWI; ADC; Gd-EOB-DTPA; Primovist; gadoxetic acid, age 
 
2.4. Introduction 
Diffusion-weighted  MRI is an emerging technique even for body applications [10,11]. The 
calculation of the apparent diffusion coefficient (ADC), by means of MR-DWI, allows the 
quantification of the combined effects of molecular Brownian motion of water within 
tissues and perfusion [5,12]. Although the DWI has been proposed to differentiate benign 
from malignant lesions or stage hepatic fibrosis [13,14] soon many limitations arose, 
especially for the liver (e.g. low spatial resolution and signal-to-noise ratio, the great 
sensitivity to movement and to magnetic susceptibility artifacts, and the lack of 
reproducibility of the obtained data). DWI is routinely used for focal liver lesions 
detection, but not for their characterization. Nowadays, its role in assessing the effects of 
therapies, is still challenging [15].  The potentiality of DWI is still controversial due to  
technical and physiological factors affecting ADC measurements, such as the b factor, the 
time of echo (TE), the site and size of sampling methods, the temperature, the diffusional 
intravoxel incoherent motion (IVIM) related to perfusion, the modality of acquisition 
(breath-hold, BH, free-breath FB, echo-navigator) [12,16–27].  Moreover, difficulties 
related to intrinsic sensitivity to motion and magnetic susceptibility of DW sequences 
should also be taken into consideration.  
Furthermore, the effects of patient’s characteristics (e.g. age) or differences related to the 
type of examination (influence of the contrast agent) on DWI has not been fully 
investigated. I think it is important to investigate these variables  in order to better 
understand which is the reproducibility and reliability of DWI parameters. 
In light of this, during the last years we studied the influence of age and contrast agent on 
DWI main quantitative parameters: ADC, PF, D and D*. 
As known, in clinical practice, DWI is usually added to acquisition protocols before CA 
administration, which are, in hepatic evaluations, often liver-specific Gd-chelates [28]. The 
most recent one of these agents is the gadoxetic acid disodium (Gd-EOB-DTPA; 
Primovist, Bayer- Schering, Berlin, Germany), is characterized by biliary excretion close 
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to 50%, which allows liver specific phase acquisitions after 10–15 minutes. The whole 
examination may be concluded in a single step without interruption.  Therefore, a time 
interval between the 5th and the 15–20th minute after the CA administration, exists. In 
order to optimize/reduce the examination time, an “inverted protocol” in which the T2w 
sequences are performed after gadoxetic acid administration, can be adopted.  This 
approach may lead to spare time during the interval between the dynamic and delayed 
hepatobiliary phases [29-31]. Trough assessing any possible change in DWI parameters, 
due to CA, we suggest the opportunity of sparing time by obtaining DWI after CA 
administration instead of before.   
2.5. Materials and Methods 
The study protocol was approved by the investigation and Ethics Committee of our 
institution for volunteers aware of aim and nature of our prospective study. Each of them 
provided a written consent before beginning the examination, in accordance with the 
principles of the Declaration of Helsinki (revision of Edinburgh, 2000). To study the 
influence of CA, the Institutional Review Board approval was waived because of the 
characteristic of the study. In fact, we added, to our standard protocol, only a DWI 
acquisition after CA administration. Each patient signed the permission form for CA 
administration where contraindications were specified, as standard procedure. All 
examinations were performed after six hours fasting. 
Patients 
Within one year (2009-2010) we prospectively  included forty healthy adult volunteers 
undergoing abdominal MR-DWI. Patient’s age covered a range included between 18 and 
>65 years. The patients were divided into four groups, ten each one, as follows:  18–30 
(group A), 31–45 (group B), 46–65 (group C), >65 years (group D). The inclusion criteria 
for this study were as follows:  
-no history of illegal drug use or alcohol abuse,  
-normal liver on ultrasound study (no focal or diffuse liver disease, including 
mild steatosis) 
-normal liver function tests and no history of abdominal surgery.  
During two months of 2011, we prospectively included all patients, with or without 
cirrhosis,  requiring  liver MR examinations with the administration of gadoxetic acid in 
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order to detect/exclude, characterize, or follow-up focal lesion(s). In this study group we 
performed a DWI sequence before and after gadoxetic acid administration. The patients 
were divided into four groups, according to the time at which the DWI sequence were 
repeated (after 5, 10, 15, and 20 minutes after the CA administration). Uncooperative 
patients were excluded from the study. 
MRI 
All patients were studied with a 1.5 T tomograph (Gyroscan NT Intera Release 12, Philips, 
Eindhoven, The Netherlands, maximum gradient strength 30 mT/m, peak slew rate 
120mT/m/msec) using a four-channel receiver coil developed for upper abdomen 
examinations. Every patient was positioned in supine position with the arms extended over 
the head in order to reduce the artifacts. As recommended, we checked the accuracy of our 
scanner with an MR-DWI phantom study [27]. The standard upper abdomen MR protocol 
is reported in table 1. 
table 1 
 
 
In the volunteers (groups A-D) the MRI was performed without CA and DW sequences set 
as follows: 
axial D-weighted echo planar (EPI) spin echo; singleshot, breath-hold sequence; b value 0–
300 s/mm2 and 0– 1000 s/mm2; TR/TE=1343/42 ms and 1867/67 ms for b value 0–300 
s/mm2 and 0–1000 s/mm2, respectively; EPI factor=39; slice thickness/number=9 mm/12; 
intersection slice gap=1 mm; flip angle=90°; sense factor 2; FOV=300–420 mm; NSA=2; 
half scan factor 62%; bandwidth 1976–1493 Hz for b value 0–300 and 0–1000 s/mm2, 
respectively; RFOV 70%; phase scan percentage 73%; acquisition voxel (mm3) 
3.32/4.55/9.00; reconstructed voxel (mm3) 1.33/1.33/9.00; acquisition matrix 128×64; 
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reconstruction matrix 320×220; acquisition time=17 and 22 s for b value 0–300 and 0–
1000 s/mm2, respectively; fat suppression obtained by spectral presaturation inversion 
recovery. Considering the 
already demonstrated liver isotropy [32], only one diffusion gradient direction was applied 
in every acquisition in order to reduce the minimum available TE and consequently the 
unwanted T2 weighting of the DW sequence. The orientation of the diffusion gradient is 
defined by the option “gradient overplus” (Philips Medical System) and the corresponding 
ADC maps were calculated (b=0–300 s/mm2, b=0–1000 s/mm2). Moreover, a smaller 
cohort of 16 subjects out of 40 were submitted to a supplemental FB, multi-b, DWI 
acquisitions (16 b value, range 0–750 s/mm2, with steps of 50 s/mm2, table 1). 
After gadoxetic acid administration, the 3D sequence was repeated during hepatic artery 
phase with a delay determined by the Care Bolus technique (mean delay time, about 30 
sec). The acquisition was repeated again at 75 seconds during portal vein phase, during the 
equilibrium phase at 180 seconds, and during the hepatobiliary phase at 5, 10, 15, and 20 
minutes. The Care Bolus technique in the sagittal and parasagittal orientations was used to 
determine the exact time to begin the artery phase acquisition, considering one scan per 
second: TR/TE=3.5/1.1 msec, slice thickness = 60 mm, intersection gap = 20%, field of 
view (FOV) = 400 mm, effective matrix size =128x128, NSA=2. The region of interest 
(ROI) with appropriate size was located in the abdominal aorta at the level of the celiac 
trunk. The Care Bolus reached the ROI level after 20–25 seconds, on average; we began 
the THRIVE sequence acquisition by an automatic breath-hold (expiratory) recorded voice 
command (given 6 sec in advance to the start of the acquisition). In these patients, 25 
mmol/kg body weight of gadoxetic acid (then 1 mL per 10 kg weight) was administered at 
1 mL/sec intravenously, as recommended, with a mechanical power injector (Spectris 
Solaris, MedRad, Indianola, PA) through a 20G catheter inserted into an antecubital vein, 
followed by a 20-mL saline flush at the same injection rate. Patients were monitored for 2 
hours after the examination to observe any adverse 
effects. 
Methods of sampling 
The DW images were evaluated by two radiologists and a physicist in consensus and then 
re-evaluated by the  study coordinator (with 4, 6, 4 and 14 years of experience in DWI, 
respectively). 
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The data (mean and SD) were collected in Regions Of Interest (ROIs) of about 1200 pixels 
manually drawn in the middle part of the right liver, excluding the focal liver lesions and 
taking care that the signal intensity coefficient of variation inside the ROI was less than 
10% at every b value.  In “CA group” patients, three averaged ROIs were drawn twice 
(before and after CA administration)  [27]. 
In five patients with focal nodular hyperplasia (FNH) we performed the DWI 
measurements also on the focal lesion between the 15‘ and 20‘ when the lesion was 
slightly more enhanced than the surrounding parenchyma [33]. 
DWI parameters  
DW images were processed using the two-compartments model of Intra Voxel Incoherent 
Motion [31], represented by the following equation   
*)exp()exp()1(
0
bDPFbDPF
S
Sb 
 (1) 
 
where S0 and Sb are respectively the signal without and with the application of the 
diffusion gradient, PF is the fraction of water diffusing and flowing in the random oriented 
capillary network, 1-PF the fraction of extravascular water, D the slow diffusion 
coefficient and D* the fast diffusion coefficient, that models the slow and the fast Intra 
Voxel Incoherent Motion, respectively.   
To determine PF, D and D* data were not simultaneously fitted over equation (1), given 
the high dispersion and the limited sampling of DWI signals at low b value (b < 150 
s/mm2) [34,35], but a two step fitting procedure was adopted, as described in other papers 
[27,36, 37]. 
PF and D were estimated from signal intensity data at high b-values (b ≥ 200 s/mm2, 
where pseudodiffusion contribution is negligible) by fitting the equation 
).exp()1(
0
bDPF
S
Sb 
  (2) 
The estimated values of PF and D were then reported in equation (1) and all multi-b (whole 
b range: 0 - 750 s/mm2) data were subsequently processed to estimate D*. 
Finally ADC was estimated fitting data to the following equation (whole b range: 0 - 750 
s/mm2): 
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)exp(
0
ADCb
S
Sb 
 (3) 
This two-steps fitting procedure was performed using a semiautomatic home-made 
software that drives the nonlinear regression algorithms provided in Gnuplot 
(http://www.gnuplot.info/, 4.4.2 release).   
Statistical analysis 
For the “age patients” group (healthy volunteers)  the ANOVA test was performed to find 
differences among ADC group means. The Pearson’s correlation coefficient (r) was 
obtained to investigate the association between ADC (b values 300 and 1000 s/mm
2
 for BH 
acquisitions and 50, 100, 150, 300 s/mm
2
 for FB acquisitions), PF, D, D* and age. The 
variation across all ages of all these DWI parameters was assessed in a linear regression 
model. In case of absence of significant correlation between DWI parameters and age, the 
mean, the SD, and the 95% limits of agreement of all the parameters were calculated 
including all the subjects. 
For the “CA group” , the data was  analyzed  “per group” and “per patient”.  
All the subjects were divided into four groups, according to the different time of the second 
DWI acquisition (5, 10, 15, 20 minutes after gadolinium injection). 
Mean and SD were calculated in each group for every DWI related parameters (PF, D, D*, 
ADC). 
All the data were tested for normality by the Shapiro-Wilk test. In case of normal 
distribution at Shapiro-Wilk test, the Dunnet test was applied to compare all the groups 
with pre-CA group. Significance threshold was set at p=0.05.  
Without a significant differences among groups , all the values of PF, D, D* and ADC, 
obtained before and after gadoxetic acid injection, were averaged by including the whole 
group of patients and by separating cirrhotic and non cirrhotic patients. 
 
2.6. Results 
The accuracy of the scanner was good (the long-term reproducibility of the ADC was 1%).  
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Forty healthy adult volunteers were included in the “age group”  (27 males, 13 females, 
age range 26-86 years, mean age 48 years). The patients were homogeneously divided into 
4 groups (A, B, C, and D) as described in Materials and Methods.  
Twenty-eight patients were enrolled in the “CA group” (four of them were excluded 
because of  non-cooperative behavior leading to strong movement artifacts on DW 
images). The remaining 24 patients (14 males, mean age 62 years, age range 25–84 years) 
were divided into 4 groups of six each, as described in Materials and Methods. Out of 24 
patients, 13 were cirrhotic and 11 non cirrhotic. In particular, in 13 cases CA was 
administered for suspicion of hepatocellular carcinoma in cirrhosis (confirmed HCC in five 
cases). The other 11 patients underwent the examination for characterization/follow-up of 
lesions with previous computed tomography and/or ultrasound and resulted in one 
hemangioma, five FNH(s), two metastasis(es), while three exams were negative for focal 
lesions. 
ADC mean, SD, and 95% confidence interval for “age group”, on BH with b value=0–300 
and 0–1000 s/mm2 DW images, were calculated and  reported for each group  (table 2).  
 
table 2 
ADC values by age group  
 
 
Apparent Diffusion Coefficient (ADC) mean, standard deviation (SD), 95% confidence interval 
(CI) for each group both at b = 300 and 1000 s/mm
2
 (data in10
-6
 mm
2
/s). 
 
 
ANOVA showed no significant differences in the mean ADC of the different groups 
(p=n.s.). No significant correlation between the subject's age and ADC was established, 
considering either BH or FB acquisition data, obtained at all the b values (50, 100, 150, 
300, 1000 s/mm
2
). No significant correlation with age was observed for PF, D and D* 
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evaluation. Pearson’s correlation coefficient for all the DWI parameters, with statistical 
significance and 95% confidence interval, were reported (table 3).  
 
table 3 
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Fig. 1 and 2 show the scatterplots with linear regression line, respectively, of BH-ADC 
values and PF, D, D* vs. age. Given the absence of significant correlation between all the 
DWI parameters and age, mean, SD and 95% confidence interval of each DWI parameter 
were calculated including all the subjects belonging to each cohort (table 3). 
fig.1 
 
Breath-hold ADC vs. age with linear regression line. Data with b=300 (A; upper) and b=1000 
s/mm2 (B; lower). The absence of a significant correlation between ADC and age, both in A and B, 
and the wide dispersion of data, more pronounced at b=300 s/mm2 (A), should be noted.  
 
 
 
 
 
 
 
 
 18 
fig. 2 
 
PF, D, D* vs. age with linear regression line. PF (A; upper), D (B; middle) and D* (C; lower) 
values. The absence of a significant correlation between PF,D, D* and age, both in A, B and C, 
should be noted. 
 
Mean , SD of PF, D, D*, and fitted ADC of each group, belonging from the “CA group”, 
are shown in table 4.  
table 4 
 
The Shapiro–Wilks test did not show any significant deviation from normality of each 
parameter distribution in each group, although with a low p value for D in the pre-CA and 
10-minute groups (p= 0.09 and 0.12, respectively) and D* in the pre-CA group (p = 0.13). 
Dunnett’s test did not show any significant difference of the averages of PF, D, D*, and 
ADC, comparing the pre-CA and the other post-CA groups (p> 0.30). The mean and SD of 
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PF, D, D*, and ADC calculated including data acquired before and after CA injection are 
reported (fig. 3). 
fig. 3 
 
Plot (mean±SD) of PF (percent), D (∙ 10-6 mm2/s), D* (∙10-3 mm2/s), and ADC (∙ 10-6 mm2/s) 
calculated using data acquired before and after the administration of contrast agent. 
  
Data considering cirrhotic and non cirrhotic patients are reported (table 5): data pre- and 
post-CA administration are substantially similar, with a slight decrease in PF and ADC in 
cirrhotic group.  
table 5 
 
Mean ± standard deviation (SD) of perfusion fraction (PF), diffusion coefficient (D,∙ 10-6 mm2/s), 
pseudodiffusion coefficient (D*, ∙10-3 mm2/s) and apparent diffusion coefficient (ADC,∙ 10-6 
mm
2
/s)  calculated before and after CA administration in patients showing and not showing liver 
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cirrhosis, respectively. No significant differences were found among before and after CA 
administration values. 
In the five patients with FNH(s), we observed that in the 20 minutes acquisition the focal 
lesion signal intensity (SI) in DWI was slightly higher with respect to the surrounding 
parenchyma. Thus, we performed an additional signal sampling for each patient, including 
in the ROI only the focal lesion. Afterwards PF, D, D*, and ADC were estimated 
considering the average signal of the FNH at every b value. The resulting maximum 
coefficient of variation, considering data acquired before and after CA injection, was =8% 
for PF, D, and ADC, while = 16% for D*. 
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2.7. Discussion  
The DWI is certainly  an interesting topic for its possible applications. In  liver imaging 
many efforts have been made and are ongoing to establish a correlation between ADC 
measurements and  liver changes. We firstly have investigated the correlation between age 
and ADC values of the liver without finding out any significant correlation, either at low-
medium b values (FB acquisitions: 50–100–150–300 s/mm2) or medium-high b values (BH 
acquisitions: 300–1000 s/mm2). 
It is well known that there is about 40% reduction in blood flow and a similar or slightly 
less reduction in liver mass during aging [38–41]. 
With a relevant reduction in liver blood flow, one would presume that there would be a 
decrease in ADC values with age, at least at lower b values. In our series, the width and 
asymmetry of ADC histograms (fig. 4) show that the ADC values are affected by a 
perfusion phenomenon, and that its spread is probably due to different components of flow 
and to a large variability in PFs.  
fig. 4 
 
Histogram of breath-hold ADC values. 
Data at b = 300 (bin size = 260 x 10
-6 
mm
2
/s) (A-left) and b = 1000 s/mm
2
 (bin size = 85 x 10
-6 
mm
2
/s)  (B-right). The higher ADC mean value at b=300 s/mm
2
 (A) compared to b=1000 s/mm
2 
(B) and the more symmetric shape of ADC distribution in (A) vs. (B) (skewness = 0.48 and 0.79, 
respectively) should be noted.  
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This probably also reflects the observed change in skewness between b=300 and b=1000 
s/mm
2
 ADC distributions and the symmetry of the D values distribution (0.48, 0.79 and 
0.06, respectively). In fact, at high b values, the diffusion component is predominant in 
ADC measurements and the residual effect of perfusion probably contributes to the 
asymmetric right tail of the ADC histograms: the absence of asymmetry in the D values 
distribution support this hypothesis. This ADC stability during different ages offers the 
possibility to use, in the future, non-age-matched groups in studies on liver ADC.  
Furthermore, the documented wide range of liver parenchyma ADC values (at b=1000 
s/mm
2) among healthy subjects, from around 1300 to 2000×10−6 mm2/s (fig. 1), suggests 
that it is improbable that this technique provides a valid mean value as a reference for all or 
at least most of the subjects. We can argue that quantitative DWI seems more useful in 
following a single subject's disease over time and is therefore more appropriate for 
longitudinal rather than cross-sectional studies. In fact, recent literature reports have shown 
that ADC is not satisfactory for distinguishing different solid focal liver lesions [42,43] or 
grading fibrosis [13–14,44]. On the contrary, results of the studies devoted to the 
evaluation and follow-up of the response of metastatic liver tumors to chemotherapy are 
hopeful [45,46]. 
To better investigate possible age-related quantitative DWI variations, we examined also 
PF, D and D
*
 in a smaller cohort of 16 volunteers (four for each age group), using a multi-
b sequence with many D weightings, which allows an highly accurate representation of 
DWI signal decay. Interestingly, we did not find any significant correlation also with these 
non-b-linked parameters and age. 
In a second group of patients we studied the effect of the CA on DWI-related parameters 
values (PF, D, D*, ADC) in patients undergoing abdominal contrast MRI to study the liver. 
In our series the parameters showed no significant differences before and after gadoxetic 
acidadministration at any time. Previous interesting articles demonstrated that there is no 
significant difference before and after administration of gadopentetate dimeglumine 
(Multihance) in the signal and contrast-to-noise ratio (CNR) of focal liver lesions and 
hepatic parenchyma [47-49]. Chiu et al. [47] found that gadoxetic acid administration does 
not compromise CNR and ADC of focal hepatic lesions, while Choi et al. [48] have shown 
that DWI after gadoxetic acid administration can be used as a substitute for unenhanced 
DWI without compromising the CNR and ADC of focal hepatic lesions. Kinner et al. [49] 
did not observe a significant difference regarding DWI in patients with cirrhosis before and 
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after CA injection. Previous studies suggest  that it is possible to perform DWI studies after 
liver-specific CA administration without compromising the signal and CNR, and ADC 
values of the most frequent focal liver lesions. However, these studies were performed 
with 3T tomography, which is not used for  liver/abdominal daily routine. Although, until 
now, DWI related parameters have not been explored. Therefore, in our study, we 
evaluated whether, the values of liver parenchyma DW-related parameters may change 
because of the use of gadoxetic acid, regardless of the patient or the disease studied. PF, D, 
D*, and fitted ADC, are less dependent on the choice of the acquisition b-values. The 
physiological interpretation proposed, for the first time, by Le Bihan et al. [4,5] is that D 
represents the slow diffusion coefficient, which describes thermal diffusion of water 
molecules (slow motion), while PF is the fraction of water molecules flowing inside the 
capillary network. Both can be estimated using a series of DW images with b >150–200 
s/mm2 (in our series until 750 with steps of 50). In their model, Le Bihan et al.,  suggested, 
the coefficient D*, as an indicator of the influence of non diffusional intravoxel incoherent 
motion on the MR-DWI signal. The coefficient D* is related to the random flow within 
capillary network (fast motion), and depends on very low b-values (under 150) [5]. It 
should be underlined that D, PF, and D* are not automatically calculated as ADC. ( maps 
obtained by commercial MR software using signal ratio from only two images, one with 
and one without D weighting). Differently, DWI parameters, are calculated by fitting the 
equations described by Le Bihan et al. The need for  a more complex model, than the 
monoexponential ADC one, arose from the observation that, in a homogeneous phantom, a 
monoexponential signal decay was expected and registered, while it was not true on DW 
signals acquired in the liver parenchyma, where a biexponential signal behavior was 
observed [4]. In our study, PF, D, D*, and fitted ADC are parameters not directly 
depending on the D-weighting of the sequence (ie, on the b-value), increasing, as a 
consequence, the range of applicability of the results. While the aforesaid article [48] 
focused on focal liver lesions, we focused on the  hepatic parenchyma.  DWI changes 
related to other factors than the disease, such as age or the administration of CA [47].  
As known, the liver SI increases  after gadoxetic acid administration until the 30° minute; 
after that, SI slowly decreases [10,50,51]. This rise in SI and then in intracellular 
concentration might have caused some modifications in the DWI related parameters. Thus, 
we decided to measure their values at various time intervals (every 5 minutes). Our results 
show that it is possible to acquire quantitative DWI at every time after CA administration 
without affecting quantitative estimations. Since already studied by others [18,29],  we did 
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not investigate the values in all the different focal liver lesions. It should to be taken into 
consideration  that the structure with the maximum concentration of gadoxetic acid after 
dynamic scans is the liver parenchyma, with rare exceptions such as FNHs and well-
differentiated HCCs in which biliary pole failures are present. For this reason we repeated 
the measures in a small pool of FNHs that demonstrated a SI higher than that measured in 
the surrounding parenchyma. Again, we found only small differences in PF, D, D*, and 
ADC calculated before and after CA administration. Moreover, the comparison between 
the PF, D, D*, and ADC values calculated on data acquired before and after CA 
administration was repeated, by dividing the patients into those with and without liver 
cirrhosis. Also in this sub-group analysis, we found only small differences. It must be 
underlined that these differences did not change the diagnostic power of PF and ADC: in 
fact, both are lower in patients affected by liver cirrhosis regardless of CA administration, 
as reported in table 5 than patients without cirrhosis. In particular, the reduction in PF 
observed in patients with diffuse liver disease could be explained with the  reduction in 
capillary network observed in cirrhotic liver. It is also noteworthy that CA administration 
did not determine a bias in all the explored parameters, as shown by the recorded values 
(fig. 3). Finally, the SD of these parameters did not change after CA injection confirming 
the evidence that Gd-EOB-DTPA does not have a significant effect on DWI 
measurements.  
In our opinion, the results of the present study, mainly the unchanged values of ADC 
before and after CA administration, are somewhat expected. In fact, the total amount of 
administered gadoxetic acid is very low (25 mmol/kg body weight) and its maximum 
blood concentration, measured immediately after bolus injection, is 0.2 mmol Gd/L. This 
very limited amount (a concentration 3 orders of magnitude lower with respect to water 
molecules flowing in the blood network) likely cannot alter the microscopic behavior of 
the water molecules, by means of its steric constraint. Moreover, it is known that all the 
Gd-chelates do not work as a linker but as a coordinator of the water molecules. This 
means that the water molecules are near, surrounding the Gd-chelate, tumbling around it, 
nevertheless remaining free and able to diffuse as happens in the absence of CA [50,51]. 
Our studies have some limitations that should be remarked. Firstly, the number of patients 
included in the study is limited. Secondly, in our scanner, echo-navigator technique is not 
available, and then we obtained multi-b sequence in FB modality, that is clearly less 
reproducible than that acquired with navigator. This is why  slice locations of paired DW 
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acquisitions may not have been perfectly matched due to patient movement and breathing 
[52].  
In conclusion, our studies indicate that there are no significant variations in liver DWI 
quantitative parameters (ADC, PF, D, and D*) depending on the age in healthy liver 
parenchyma or after gadoxetic acid administration. 
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